Publication: Comparison of imipenem and ceftazidime as therapy for severe melioidosis
Issued Date
1999-01-01
Resource Type
ISSN
10584838
DOI
Other identifier(s)
2-s2.0-0032777243
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.29, No.2 (1999), 381-387
Suggested Citation
Andrew J.H. Simpson, Yupin Suputtamongkol, Michael D. Smith, Brian J. Angus, Adul Rajanuwong, Vanaporn Wuthiekanun, Paul A. Howe, Amanda L. Walsh, Wipada Chaowagul, Nicholas J. White Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clinical Infectious Diseases. Vol.29, No.2 (1999), 381-387. doi:10.1086/520219 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25765
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of imipenem and ceftazidime as therapy for severe melioidosis
Abstract
An open, prospective, randomized, comparative treatment trial was conducted to compare the therapeutic efficacy of high-dose intravenous imipenem and ceftazidime for acute severe melioidosis. Adult Thai patients with suspected acute, severe melioidosis were randomized to receive either imipenem, at a dosage of 50 mg/(kg · d), or ceftazidime, at a dosage of 120 mg/(kg · d), for a minimum of 10 days. The main outcome measures were death or treatment failure. Of the 296 patients enrolled, 214 had culture-confirmed melioidosis, and 132 (61.7%) of them had positive blood cultures. Mortality among patients with melioidosis was 36,9% overall. There were no differences in survival overall (P = .96) or after 48 hours (P = .3). Treatment failure after 48 hours was more common among patients treated with ceftazidime (P = .011). Both treatments were well tolerated. Imipenem is a safe and effective treatment for acute severe melioidosis and may be considered an alternative to ceftazidime.